The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

The regulatory landscape for device-based heart failure (HF) therapies has seen a major
shift in the last 7 years. In 2013, the US Food and Drug Administration released guidance for …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

5.2. 1. Ocena funkcji skurczowej lewej komory...................................... 1052 5.2. 2. Ocena
funkcji rozkurczowej lewej komory...................................... 1052 5.2. 3. Ocena funkcji prawej …

Importance There is limited evidence on the benefits of sacubitril/valsartan vs broader renin
angiotensin system inhibitor background therapy on surrogate outcome markers, 6-minute …

Background: Heart failure (HF) is increasing in prevalence and is a major cause of morbidity
and mortality despite advances in medical and device therapy. Autonomic imbalance, with …

Background This study demonstrated the safety and effectiveness of baroreflex activation
therapy (BAT) in patients with heart failure with reduced ejection fraction (HFrEF). Objectives …

Se recomienda a los profesionales de la salud que tengan en consideración la presente
guía de la ESC en la toma de decisiones clínicas en su ejercicio diario, así como en la …

Most of the current heart failure (HF) prevention or management programs assume that
cardiovascular decompensations are primarily driven by volume overload that result in …

Worsening heart failure (WHF) is a severe and dynamic condition characterized by
significant clinical and hemodynamic deterioration. It is characterized by worsening HF …